Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CXS 299

Drug Profile

CXS 299

Alternative Names: CXS-299; DACH-Ac-Pt (IV); DACH-acetato-Pt; DAP

Latest Information Update: 02 Feb 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer ChemGenex Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action DNA inhibitors; Mitosis inhibitors; Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 02 Feb 2009 Suspended - Preclinical for Cancer in Australia (unspecified route)
  • 14 Jun 2007 Preclinical development is ongoing
  • 11 Feb 2005 Preclinical trials in Cancer in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top